Less Ads, More Data, More Tools Register for FREE

Monday broker round-up

Mon, 11th Jun 2012 09:37
Antofagasta: RBS Capital Markets downgrades to underperform.Ashtead: Jefferies keeps buy recommendation and 300p target.Barclays: Bank of America Merrill Lynch keeps buy rating and 370p target; Oriel Securities reiterates buy recommendation and 285p target.BP: Nomura retains neutral stance and 500p target.Craneware: Investec upgrades from hold to buy, target cut from 405p to 390p.ENRC: RBC Capital Markets downgrades to underperform.Flybe: Investec ups target from 70p to 89p, hold rating kept; Oriel Securities reiterates reduce recommendation.GlaxoSmithKline: Credit Suisse keeps neutral rating and 1,430p target.Helical Bar: Oriel Securities upgrades to buy.HSBC: Oriel Securities reiterates reduce recommendation and 550p target.International Consolidated Airlines Group: Nomura maintains buy rating and 265p target.Johnson Matthey: Numis downgrades to add. target cut from 2,660p to 2,664p.Lamprell: Investec slashes target from 200p to 100p, hold rating kept.Lloyds: Oriel Securities reiterates buy recommendation and 45p target.Royal Bank of Scotland: Oriel Securities reiterates buy recommendation and 40p target.Serco: Investec reiterates buy recommendation and 620p target; Oriel Securities reiterates reduce recommendation and 500p target.Smiths Group: Jefferies maintains buy rating and 1,600p target.Standard Chartered: Oriel Securities reiterates buy recommendation and 1,900p target.Tate & Lyle: Societe General upgrades to hold.Tesco: Nomura reiterates buy rating and 430p target; Oriel Securities reiterates reduce recommendation and 280p target; Credit Suisse keeps neutral rating and 370p target.WH Smith: Nomura keeps buy recommendation and 600p target.BC International Airlines Tesco Barclays Lloyds Wh Smith HSBC Holdings Helical Bar Tate & Lyle Johnson Matthey Standard Chartered Serco Craneware Smiths Group Glaxosmithkline Antofagasta

Shares in this article

Related News

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
1 day ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
1 day ago

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial

(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...

GSK hails 'milestone' drug trial results in China
1 day ago

GSK hails 'milestone' drug trial results in China

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...